Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious program, conolidine modulates alternate molecular targets. A Science Innovations analyze found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://laneyyqql.blogstival.com/59946837/conolidin-to-replace-traditional-painkillers-options